Combination of biochanin a and temozolomide impairs tumor growth by modulating cell metabolism in glioblastoma multiforme

29Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Several epidemiological studies have reported the chemopreventive potential of biochanin A, in cancer development and progression. We investigated the anticancer potential of combination of biochanin A and temozolomide against U-87 MG and T98 G [glioblastoma multiforme (GBM)] cells. Materials and Methods: We evaluated the effect of biochanin A and temozolomide treatment on cell viability, expression of survival proteins, cell cycle, cell metabolism and mitochondrial function. Results: Enhanced inhibitory effects of the combination treatment were observed on cell viability, expression of cell survival proteins EGFR, pERK, p-AKT, c-myc and MT-MMP1, and increased expression of the tumor suppressor, p-p53. Combination treatment also induced arrest in the G 1 phase of the cell cycle. A shift in the metabolic phenotype of cells from glycolytic to oxidative phosphorylation was observed on combination treatment and the permeabilized cells showed a significant impairment in complex IV activity. Conclusion: Biochanin A significantly enhanced the anticancer efficacy of temozolomide in GBM cells.

Cite

CITATION STYLE

APA

Desai, V., Jain, A., Shaghaghi, H., Summer, R., Lai, J. C. K., & Bhushan, A. (2019). Combination of biochanin a and temozolomide impairs tumor growth by modulating cell metabolism in glioblastoma multiforme. Anticancer Research, 39(1), 57–66. https://doi.org/10.21873/anticanres.13079

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free